Related references
Note: Only part of the references are listed.Estrogen Receptor-Positive Breast Cancer: Exploiting Signaling Pathways Implicated in Endocrine Resistance
Adam M. Brufsky et al.
ONCOLOGIST (2018)
Defining the optimal sequence for the systemic treatment of metastatic breast cancer
J. A. Mestres et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2017)
Acquired CDK6 amplification promotes breast cancer resistance to CDK4/6 inhibitors and loss of ER signaling and dependence
C. Yang et al.
ONCOGENE (2017)
Pharmacokinetic drug evaluation of ribociclib for the treatment of metastatic, hormone-positive breast cancer
Giuseppe Curigliano et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2017)
Biomarkers of Everolimus Sensitivity in Hormone Receptor-Positive Breast Cancer
Zongbi Yi et al.
JOURNAL OF BREAST CANCER (2017)
Characterization of patient-derived tumor xenografts (PDXs) as models for estrogen receptor positive (ER+HER2-and ER+HER2+) breast cancers
Noriko Kanaya et al.
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY (2017)
Rapid Breast Cancer Disease Progression Following Cyclin Dependent Kinase 4 and 6 Inhibitor Discontinuation
Sami I. Bashour et al.
JOURNAL OF CANCER (2017)
Combined Inhibition of CDK4/6 and PI3K/AKT/mTOR Pathways Induces a Synergistic Anti-Tumor Effect in Malignant Pleural Mesothelioma Cells
Mara A. Bonelli et al.
NEOPLASIA (2017)
The next era of treatment for hormone receptor-positive, HER2-negative advanced breast cancer: Triplet combination-based endocrine therapies
Javier Cortes et al.
CANCER TREATMENT REVIEWS (2017)
mTOR Signaling in Growth, Metabolism, and Disease (vol 168, pg 960, 2017)
Robert A. Saxton et al.
CELL (2017)
A Phase I Trial of BKM120 (Buparlisib) in Combination with Fulvestrant in Postmenopausal Women with Estrogen Receptor-Positive Metastatic Breast Cancer
Cynthia X. Ma et al.
CLINICAL CANCER RESEARCH (2016)
A Phase I Study of the AKT Inhibitor MK-2206 in Combination with Hormonal Therapy in Postmenopausal Women with Estrogen Receptor-Positive Metastatic Breast Cancer
Cynthia X. Ma et al.
CLINICAL CANCER RESEARCH (2016)
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
Massimo Cristofanilli et al.
LANCET ONCOLOGY (2016)
Inhibition of Rb Phosphorylation Leads to mTORC2-Mediated Activation of Akt
Jinfang Zhang et al.
MOLECULAR CELL (2016)
Palbociclib and Letrozole in Advanced Breast Cancer
Richard S. Finn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study
Richard S. Finn et al.
LANCET ONCOLOGY (2015)
Preclinical trial of a new dual mTOR inhibitor, MLN0128, using renal cell carcinoma tumorgrafts
Alexandre Ingels et al.
INTERNATIONAL JOURNAL OF CANCER (2014)
Stand Up to Cancer Phase Ib Study of Pan-Phosphoinositide-3-Kinase Inhibitor Buparlisib With Letrozole in Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer
Ingrid A. Mayer et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
The PI3K/AKT/mTOR pathway in breast cancer: targets, trials and biomarkers
Elisavet Paplomata et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2014)
mTORC1 Inhibition Is Required for Sensitivity to PI3K p110α Inhibitors in PIK3CA-Mutant Breast Cancer
Moshe Elkabets et al.
SCIENCE TRANSLATIONAL MEDICINE (2013)
Overcoming breast cancer drug resistance with mTOR inhibitors. Could it be a myth or a real possibility in the short-term future?
Nadia Margariti et al.
BREAST CANCER RESEARCH AND TREATMENT (2011)
Clinical significance of estrogen receptor phosphorylation
Leigh C. Murphy et al.
ENDOCRINE-RELATED CANCER (2011)
Pushing the Envelope in the mTOR Pathway: The Second Generation of Inhibitors
Eduardo Vilar et al.
MOLECULAR CANCER THERAPEUTICS (2011)
Pancreatic Endocrine Tumors: Expression Profiling Evidences a Role for AKT-mTOR Pathway
Edoardo Missiaglia et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Molecular characterization of aromatase inhibitor-resistant, tamoxifen-resistant and LTEDaro cell lines
Selma Masri et al.
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY (2010)
New experimental models for aromatase inhibitor resistance
Shiuan Chen et al.
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY (2007)
Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism
X. Wan et al.
ONCOGENE (2007)
mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt
KE O'Reilly et al.
CANCER RESEARCH (2006)
Share Paper
